Education
About Us
Working with TipRanks
Follow Us
Jade Biosciences (JBIO)
NASDAQ:JBIO
JBIO Stock Chart & Stats
$9.78
--
Market closed
$9.78
--
Day’s Range― - ―
52-Week Range$6.57 - $105.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)120.26K
Market Cap
$319.25M
Enterprise Value$63.88M
Total Cash (Recent Filing)$220.94M
Total Debt (Recent Filing)$792.00K
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Nov 17, 2025EPS Estimate
-0.67Last Dividend Ex-Date
Apr 29, 2025Dividend Yield24.53%
Share Statistics
EPS (TTM)-0.86
Shares Outstanding32,626,730
10 Day Avg. Volume231,378
30 Day Avg. Volume120,259
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-281.41
Enterprise Value/Ebitda-1.19
Forecast
1Y Price Target
$23.00Price Target Upside135.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Leadership And ExperienceThe CEO and CSO of Jade have significant experience in the space, having been part of the leadership team at Chinook Therapeutics, which was acquired by Novartis for $3.2B upfront.
Market OpportunityIgAN represents a large market opportunity that likely exceeds $10B in the US alone with limited treatment options that directly address the cause of the disease.
Product DifferentiationJADE101’s differentiated PK features are expected to translate into a potentially class-leading clinical profile.
Bears Say
Clinical DevelopmentThe Phase Ia trial is on track to initiate soon, with data expected to provide key insights into JADE101's performance.
CompetitionJADE101 could emerge as a preferred treatment option as APRIL inhibitors have demonstrated deeper reductions of Gd-IgA1 compared to the currently approved therapy, Tarpeyo.
Jade Biosciences News
JBIO FAQ
What was Jade Biosciences’s price range in the past 12 months?
Jade Biosciences lowest stock price was $6.57 and its highest was $105.00 in the past 12 months.
What is Jade Biosciences’s market cap?
Jade Biosciences’s market cap is $319.25M.
When is Jade Biosciences’s upcoming earnings report date?
Jade Biosciences’s upcoming earnings report date is Nov 17, 2025 which is in 30 days.
How were Jade Biosciences’s earnings last quarter?
Jade Biosciences released its earnings results on Aug 13, 2025. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.433 by -$0.427.
Is Jade Biosciences overvalued?
According to Wall Street analysts Jade Biosciences’s price is currently Undervalued.
Does Jade Biosciences pay dividends?
Jade Biosciences pays a Notavailable dividend of $2.4 which represents an annual dividend yield of 24.53%. See more information on Jade Biosciences dividends here
What is Jade Biosciences’s EPS estimate?
Jade Biosciences’s EPS estimate is -0.67.
How many shares outstanding does Jade Biosciences have?
Jade Biosciences has 32,626,730 shares outstanding.
What happened to Jade Biosciences’s price movement after its last earnings report?
Jade Biosciences reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.433. Following the earnings report the stock price went down -7.64%.
Which hedge fund is a major shareholder of Jade Biosciences?
Currently, no hedge funds are holding shares in JBIO
Jade Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.00 (135.17% Upside)
$23.00 (135.17% Upside)
Hedge Fund Trend
Increased
By 7.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.39%
12-Months-Change
Fundamentals
Return on Equity
-38.06%
Trailing 12-Months
Asset Growth
100.52%
Trailing 12-Months
Company Description
Jade Biosciences
Aerovate Therapeutics (AVTE) is a biotechnology company focused on developing innovative therapies for severe respiratory diseases. The company operates within the pharmaceutical and biotechnology sectors, specializing in the research and development of novel treatments aimed at addressing unmet medical needs in pulmonary arterial hypertension (PAH) and other serious conditions. Aerovate's core product pipeline includes AV-101, an inhaled dry powder formulation of imatinib, designed to improve the lives of patients suffering from PAH.
JBIO Stock 12 Month Forecast
Average Price Target
$23.00
▲(135.17% Upside)
Technical Analysis
Ownership Overview
4.08% Insiders
5.36% Mutual Funds
64.41% Other Institutional Investors
17.52% Public Companies and
Individual Investors